Nicox S.A. has enrolled the first 10 patients in a phase 2 study of NCX 470, a nitric oxide-donating prostaglandin analog, for the reduction of IOP, according to a press release.
The multicenter, double-masked, parallel group, dose-ranging study will compare the safety and efficacy of NCX 470 against latanoprost 0.005% in 420 adults with open-angle glaucoma or ocular hypertension, the release said.
“NCX 470 is a new chemical entity which uses bimatoprost, a prostaglandin analog, as a scaffold for attaching an NO-donating moiety in order to achieve a dual mechanism (Read more...)
Uncategorized